Literature DB >> 1865080

Coexisting hyperparathyroidism with thyrotoxicosis.

D M McGowan1, A Vaswani, I Shperling.   

Abstract

The coexistence of hyperparathyroidism complicating thyrotoxicosis is quite rare. We report the case of one patient who presented with thyrotoxicosis, (total thyroxine of 15.1 micrograms/dl (5-13), free thyroxine index of 18 (4-15) and triiodothyronine by RIA of 305 ng/dl (70-230) and asymptomatic hypercalcemia of 15 mg/dl (8.5-10.6), who was also initially noted to have an elevated (C-terminal) serum immunoreactive parathyroid hormone (iPTH) level of 8,800 pg/ml (50-340). With propylthiouracil and propranolol, however, this patient became normocalcemic with a decrease in iPTH values to 714 pg/ml. As the patient was tapered from medication, after being rendered euthyroid, a recurrence of hypercalcemia with rising iPTH levels occurred. PTH levels should be helpful in defining coexisting hyperparathyroidism in patients with thyrotoxicosis since in the latter iPTH is usually suppressed. Our findings support the recommendation that in patients suspected of having both hyperparathyroidism and hyperthyroidism, a diagnosis of the former can only be made with certainty after the patient has been rendered euthyroid with persistently elevated serum calcium and iPTH levels. While there are no clinical features which permit the easy identification of patients who present with dual lesions, the determination of iPTH values may be the most consistently helpful test initially, whereas other parameters such as vitamin D, serum phosphate are less reliable.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1865080     DOI: 10.1007/bf03346819

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  33 in total

1.  Treatment of thyrotoxic hypercalcemia with propranolol.

Authors:  R K Rude; S B Oldham; F R Singer; J T Nicoloff
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

2.  Ionized and total serum calcium and parathyroid hormone in hyperthyroidism.

Authors:  K D Burman; J M Monchik; J M Earll; L Wartofsky
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

Review 3.  Thyroid hormone and the kidney.

Authors:  A I Katz; D S Emmanouel; M D Lindheimer
Journal:  Nephron       Date:  1975       Impact factor: 2.847

4.  Intestinal calcium absorption in patients with hyperthyroidism.

Authors:  B Haldimann; E M Kaptein; F R Singer; J T Nicoloff; S G Massry
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

5.  Thyrotoxicosis: comparison of effects of thyroid ablation and beta-adrenergic blockade on metabolic rate and ventilatory control.

Authors:  C W Zwillich; M Matthay; D E Potts; R Adler; F Hofeldt; J V Weil
Journal:  J Clin Endocrinol Metab       Date:  1978-03       Impact factor: 5.958

6.  Acute parathyroid hormone response to epinephrine in vivo.

Authors:  J A Fischer; J W Blum; U Binswanger
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

7.  Symptomatic hypercalcaemia in thyrotoxicosis.

Authors:  R G Twycross; V Marks
Journal:  Br Med J       Date:  1970-06-20

8.  Hyperparathyroidism with coexisting hyperthyroidism.

Authors:  N B Ackerman; R F Arribas
Journal:  Am J Surg       Date:  1976-11       Impact factor: 2.565

9.  Hypercalcemia in thyrotoxicosis.

Authors:  H R Maxon; D J Apple; R E Goldsmith
Journal:  Surg Gynecol Obstet       Date:  1978-11

10.  Concomitant Graves' disease and primary hyperparathyroidism. Influence of hyperthyroidism on serum calcium and parathyroid hormone.

Authors:  R Arem; M A Lim-Abrahan; L E Mallette
Journal:  Am J Med       Date:  1986-04       Impact factor: 4.965

View more
  7 in total

1.  Hyperparathyroidism associated with hyperthyroidism.

Authors:  M Terzolo; A Piovesan; G Osella; P Caraci; F Orlandi; A Angeli
Journal:  J Endocrinol Invest       Date:  1992-02       Impact factor: 4.256

2.  Hypercalcaemia.

Authors:  S Vijayaraghavan; A Jones; D F Wood; J P Monson
Journal:  Postgrad Med J       Date:  1997-01       Impact factor: 2.401

3.  Coexistence of Graves' disease and primary hyperparathyroidism: a case description.

Authors:  Fang Zhang; Xiaohui Pan; Nanwei Tong; Qingguo Lü
Journal:  Quant Imaging Med Surg       Date:  2022-05

4.  Transient hyperthyroidism after surgery for secondary hyperparathyroidism: a common problem.

Authors:  Gottfried Rudofsky; M Tsioga; P Reismann; C Leowardi; S Kopf; I A Grafe; P P Nawroth; B Isermann
Journal:  Eur J Med Res       Date:  2011-08-08       Impact factor: 2.175

5.  Case report: coexistence of primary hyperparathyroidism with giant toxic nodular goiter.

Authors:  Wei Zhang; Fangyi Liu; Kang Chen; Yajing Wang; Jingtao Dou; Yiming Mu; Zhaohui Lyu; Li Zang
Journal:  BMC Endocr Disord       Date:  2022-08-09       Impact factor: 3.263

6.  CO-EXISTENCE OF PRIMARY HYPERPARATHYROIDISM DUE TO MULTIPLE ENDOCRINE NEOPLASIA 1 IN A HYPERCALCEMIC PATIENT WITH GRAVES DISEASE.

Authors:  Shalini Bhat; Susan Davis
Journal:  AACE Clin Case Rep       Date:  2019-01-30

7.  Transient Thyroiditis after Surgery for Tertiary Hyperparathyroidism: A Case Report.

Authors:  Yasser Ali Hakami
Journal:  Front Endocrinol (Lausanne)       Date:  2015-08-18       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.